263 related articles for article (PubMed ID: 30087439)
1. ATP in the tumour microenvironment drives expression of nfP2X
Gilbert SM; Oliphant CJ; Hassan S; Peille AL; Bronsert P; Falzoni S; Di Virgilio F; McNulty S; Lara R
Oncogene; 2019 Jan; 38(2):194-208. PubMed ID: 30087439
[TBL] [Abstract][Full Text] [Related]
2. Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death.
Draganov D; Gopalakrishna-Pillai S; Chen YR; Zuckerman N; Moeller S; Wang C; Ann D; Lee PP
Sci Rep; 2015 Nov; 5():16222. PubMed ID: 26552848
[TBL] [Abstract][Full Text] [Related]
3. The second transmembrane domain of P2X7 contributes to dilated pore formation.
Sun C; Heid ME; Keyel PA; Salter RD
PLoS One; 2013; 8(4):e61886. PubMed ID: 23613968
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for the functional properties of the P2X7 receptor for extracellular ATP.
Jiang LH; Caseley EA; Muench SP; Roger S
Purinergic Signal; 2021 Sep; 17(3):331-344. PubMed ID: 33987781
[TBL] [Abstract][Full Text] [Related]
5. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment.
Di Virgilio F; Sarti AC; Falzoni S; De Marchi E; Adinolfi E
Nat Rev Cancer; 2018 Oct; 18(10):601-618. PubMed ID: 30006588
[TBL] [Abstract][Full Text] [Related]
6. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives.
Roger S; Jelassi B; Couillin I; Pelegrin P; Besson P; Jiang LH
Biochim Biophys Acta; 2015 Oct; 1848(10 Pt B):2584-602. PubMed ID: 25450340
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical validation of a pan-cancer CAR-T cell immunotherapy targeting nfP2X7.
Bandara V; Foeng J; Gundsambuu B; Norton TS; Napoli S; McPeake DJ; Tyllis TS; Rohani-Rad E; Abbott C; Mills SJ; Tan LY; Thompson EJ; Willet VM; Nikitaras VJ; Zheng J; Comerford I; Johnson A; Coombs J; Oehler MK; Ricciardelli C; Cowin AJ; Bonder CS; Jensen M; Sadlon TJ; McColl SR; Barry SC
Nat Commun; 2023 Sep; 14(1):5546. PubMed ID: 37684239
[TBL] [Abstract][Full Text] [Related]
8. Contribution of the Juxtatransmembrane Intracellular Regions to the Time Course and Permeation of ATP-gated P2X7 Receptor Ion Channels.
Allsopp RC; Evans RJ
J Biol Chem; 2015 Jun; 290(23):14556-66. PubMed ID: 25903136
[TBL] [Abstract][Full Text] [Related]
9. The P2X7 receptor supports both life and death in fibrogenic pancreatic stellate cells.
Haanes KA; Schwab A; Novak I
PLoS One; 2012; 7(12):e51164. PubMed ID: 23284663
[TBL] [Abstract][Full Text] [Related]
10. P2X7 receptor activation impairs antitumour activity of natural killer cells.
Baroja-Mazo A; Peñín-Franch A; Lucas-Ruiz F; de Torre-Minguela C; Alarcón-Vila C; Hernández-Caselles T; Pelegrín P
Br J Pharmacol; 2023 Jan; 180(1):111-128. PubMed ID: 36098250
[TBL] [Abstract][Full Text] [Related]
11. Engineered CAR-T cells targeting the non-functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancer.
Bandara V; Niktaras VM; Willett VJ; Chapman H; Lokman NA; Macpherson AM; Napoli S; Gundsambuu B; Foeng J; Sadlon TJ; Coombs J; McColl SR; Barry SC; Oehler MK; Ricciardelli C
Clin Transl Immunology; 2024; 13(5):e1512. PubMed ID: 38800555
[TBL] [Abstract][Full Text] [Related]
12. P2X7 receptor antagonism in the treatment of cancers.
Roger S; Pelegrin P
Expert Opin Investig Drugs; 2011 Jul; 20(7):875-80. PubMed ID: 21619470
[TBL] [Abstract][Full Text] [Related]
13. P2X7 Variants in Oncogenesis.
Pegoraro A; De Marchi E; Adinolfi E
Cells; 2021 Jan; 10(1):. PubMed ID: 33477845
[TBL] [Abstract][Full Text] [Related]
14. Human P2Y
Dreisig K; Sund L; Dommer MW; Kristensen NP; Boddum K; Viste R; Fredholm S; Odum N; Jäättelä M; Skov S; Kornum BR
Front Immunol; 2018; 9():1159. PubMed ID: 29937766
[TBL] [Abstract][Full Text] [Related]
15. P2X7 Receptors and TMEM16 Channels Are Functionally Coupled with Implications for Macropore Formation and Current Facilitation.
Dunning K; Martz A; Peralta FA; Cevoli F; Boué-Grabot E; Compan V; Gautherat F; Wolf P; Chataigneau T; Grutter T
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207150
[TBL] [Abstract][Full Text] [Related]
16. ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment.
Bianchi G; Vuerich M; Pellegatti P; Marimpietri D; Emionite L; Marigo I; Bronte V; Di Virgilio F; Pistoia V; Raffaghello L
Cell Death Dis; 2014 Mar; 5(3):e1135. PubMed ID: 24651438
[TBL] [Abstract][Full Text] [Related]
17. [Purinergic P2X family and specific features of the P2X7 subtype].
Jindrichová M; Zemková H
Cesk Fysiol; 2013; 62(2):40-6. PubMed ID: 24392594
[TBL] [Abstract][Full Text] [Related]
18. Effect of P2X7 receptor on tumorigenesis and its pharmacological properties.
Zhang WJ; Hu CG; Zhu ZM; Luo HL
Biomed Pharmacother; 2020 May; 125():109844. PubMed ID: 32004973
[TBL] [Abstract][Full Text] [Related]
19. P2X7 receptor stimulates breast cancer cell invasion and migration via the AKT pathway.
Xia J; Yu X; Tang L; Li G; He T
Oncol Rep; 2015 Jul; 34(1):103-10. PubMed ID: 25976617
[TBL] [Abstract][Full Text] [Related]
20. P2X7 receptors trigger ATP exocytosis and modify secretory vesicle dynamics in neuroblastoma cells.
Gutiérrez-Martín Y; Bustillo D; Gómez-Villafuertes R; Sánchez-Nogueiro J; Torregrosa-Hetland C; Binz T; Gutiérrez LM; Miras-Portugal MT; Artalejo AR
J Biol Chem; 2011 Apr; 286(13):11370-81. PubMed ID: 21292765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
